HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antiperspirant Labeling Determined Appropriate In FDA Petition Denial

This article was originally published in The Rose Sheet

Executive Summary

Modified labeling is not necessary for OTC antiperspirants because they can readily incorporate the information required under the final monograph in the "Drug Facts" format, FDA says in a letter to the Cosmetic, Toiletry and Fragrance Association
Advertisement

Related Content

Inhalation Warnings For Aerosolized Antip/Deo Is Not Redundant – FDA
Inhalation Warnings For Aerosolized Antip/Deo Is Not Redundant – FDA
FDA Antiperspirant Monograph Partial Stay Permits Enhanced Duration
Aluminum-Containing Antiperspirant Renal Warning Mandated By FDA
Antiperspirant OTC Labeling Flexibility Requested By CTFA
Antiperspirant OTC Labeling Flexibility Requested By CTFA
Advertisement
UsernamePublicRestriction

Register

RS012598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel